Drugs / Carboplatin
Carboplatin
Drug FDA approvedPlatinum-based antineoplastic·First approved·1989
- Registered trials
- 2332
- Ongoing
- 671/ 29%
- Completed
- 1075
- Indications
- 5
Approved indications
| Indication |
|---|
| Ovarian cancer |
| Lung cancer |
| Head and neck cancer |
| Brain cancer |
| Neuroblastoma |
Clinical trial landscape
2332 registered studies reference this molecule or one of its brands. The split below shows how many are ongoing versus completed per phase.
| Phase | Total | Ongoing | Completed | Split |
|---|---|---|---|---|
| Phase 2 | 1103 | 309 | 513 | |
| Phase 3 | 483 | 171 | 209 | |
| Phase 1 | 369 | 69 | 214 | |
| Phase 1/2 | 240 | 70 | 94 | |
| Phase 2/3 | 47 | 25 | 11 | |
| Not applicable | 33 | 8 | 13 | |
| Unknown | 24 | 6 | 13 | |
| Phase 4 | 19 | 6 | 6 | |
| Early Phase 1 | 14 | 7 | 2 | |
| All phases | 2332 | 671 | 1075 |
Ongoing Completed Balance withdrawn, terminated, or status unreported.
Study records: ClinicalTrials.gov →
Mechanism of action
Binds and cross-links DNA, interfering with replication and suppressing cancer cell growth.
Recent developments
Headlines link to the original publisher. Sources limited to a reviewed list of journals, regulators, and medical press.